S. 3794, the SAFE Drugs Act of 2026, advanced out of committee on July 22, 2026.

What it does

This bill tightens FDA oversight of compounding pharmacies and outsourcing facilities by capping how many times they can compound copies of commercially available drugs (20 times per month), requiring reporting when they compound such drugs for out-of-state patients, and mandating more frequent FDA inspections of large-scale outsourcing facilities. The bill aims to prevent compounding pharmacies from operating as unlicensed drug manufacturers while preserving their ability to customize medications for individual patients with genuine medical needs.

Quorum's transparency scan gave SAFE Drugs Act of 2026 a moderate transparency flag.

What happens next

S. 3794 advanced out of committee. Next stop: a floor vote.

Who is behind it

Filed by Jim Banks. Cosponsored by Martin Heinrich.